HUTCHMED (China) Limited (HCM) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $15.21. It has a SharesGrow Score of 81/100, indicating a strong investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of HCM = $42.95 (+182.4% from the current price, the stock appears undervalued). Analyst consensus target is HCM = $18 (+15.1% upside).
Valuation: HCM trades at a trailing Price-to-Earnings (P/E) of 5.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.12.
Financials: revenue is $550M, +19.7%/yr average growth. Net income is $458M, growing at +392.1%/yr. Net profit margin is 83.3% (strong). Gross margin is 38.7% (+11.7 pp trend).
Balance sheet: total debt is $98M against $1.2B equity (Debt-to-Equity (D/E) ratio 0.08, conservative). Current ratio is 4.96 (strong liquidity). Debt-to-assets is 5.6%. Total assets: $1.8B.
Analyst outlook: 8 / 10 analysts rate HCM as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 90/100 (Pass), Past 75/100 (Partial), Health 67/100 (Partial), Moat 56/100 (Partial), Future 88/100 (Pass), Income 100/100 (Pass).
